10.4 Platelet Disorders | Neonatology Academy

Bedside Safety Message

Five questions before any platelet transfusion decision

Do not treat the platelet number alone. First ask:

Is the baby bleeding?
Is the baby clinically sick?
Is the thrombocytopenia early or late?
Is this a well term infant with severe thrombocytopenia → treat as NAIT until proven otherwise.
Would transfusion help or harm this specific infant right now?

Platelet transfusion can be life-saving, but unnecessary prophylactic transfusion in stable preterm infants may cause harm (PlaNeT-2 evidence).

Source synthesis: Baylor 2025–2026 is the primary structure; West Midlands 2025–2028 and Belize 2018–2021 are integrated with PlaNeT-2/MATISSE evidence updates. Harmonize with local blood-bank availability and pediatric hematology advice.

1. Definitions and Clinical Significance

Term	Practical Definition	Clinical Meaning
Neonatal thrombocytopenia	Platelet count <150 × 10⁹/L (<150,000/µL).	Common in sick NICU infants; severe thrombocytopenia in a well term infant is unusual and should trigger urgent NAIT evaluation.
Mild thrombocytopenia	100–150 × 10⁹/L.	Often transient in preterm or placental-insufficiency infants; monitor trend and clinical context.
Moderate thrombocytopenia	50–99 × 10⁹/L.	Requires assessment for sepsis, NEC, DIC, congenital infection, maternal disease, drugs, placental insufficiency, or immune causes.
Severe thrombocytopenia	<50 × 10⁹/L.	Higher bleeding risk; obtain careful bleeding assessment, consider coagulation screen, and discuss with hematology/transfusion medicine when unexplained.
Very severe thrombocytopenia	<20–25 × 10⁹/L.	Usually prompts platelet transfusion even if not bleeding, depending on gestation, stability, NAIT risk, and local policy.
NAIT / FNAIT	Maternal alloantibodies against fetal platelet antigens inherited from the father.	May affect the first pregnancy; severe thrombocytopenia, petechiae, or intracranial hemorrhage in a well newborn is NAIT until proven otherwise.
NAUMT	Maternal autoimmune antibodies from ITP, SLE, or similar conditions affect both maternal and neonatal platelets.	Usually milder than NAIT, but platelet nadir often occurs days 2–5 and requires follow-up monitoring.

High-risk recognition shortcut

A term or preterm infant younger than 7 days who is otherwise well but has platelet count <50 × 10⁹/L, petechiae, purpura, or unexplained intracranial bleeding should be managed as suspected NAIT immediately. Do not wait for confirmatory serology before transfusing when thresholds are met.

2. First 10 Minutes: Bedside Assessment and Stabilization

Confirm the result. Repeat a venous or arterial sample if platelet clumping, heel-stick artifact, or line contamination is possible; review smear if available.
Assess severity and bleeding. Look for petechiae, purpura, oozing, mucosal bleeding, GI blood, hematuria, pulmonary hemorrhage, IVH, or hemodynamic instability.
Classify timing. Early-onset thrombocytopenia is within the first 72 hours; late-onset (after 72 hours) should raise concern for sepsis, NEC, thrombosis, or evolving systemic illness.
Classify the baby as well or sick. A well infant suggests immune, placental, congenital, or inherited causes; a sick infant suggests infection, NEC, DIC, hypoxia, thrombosis, or multiorgan disease.
Protect the baby while evaluating. Avoid heel sticks, intramuscular injections, circumcision, unnecessary central lines, lumbar puncture, or chest drains until the risk is reviewed.
Call early. Consult pediatric hematology and transfusion medicine for severe unexplained thrombocytopenia, suspected NAIT, active bleeding, refractory thrombocytopenia, or need for special platelets.

3. Differential Diagnosis by Clinical Pattern

Pattern	Likely Causes	Clues	Immediate Tests / Actions
Well baby, early onset (<72 h), mild–moderate	Placental insufficiency, IUGR/SGA, maternal hypertension/preeclampsia, maternal diabetes.	Usually preterm or growth-restricted; platelet count often 50–150 × 10⁹/L and improves over 1–2 weeks.	Repeat count/trend; no extensive workup if clear placental story and improving.
Well baby, early onset, severe (<50 × 10⁹/L)	NAIT, maternal autoimmune thrombocytopenia, congenital infection, inherited thrombocytopenia, trisomy.	Petechiae/purpura; mother may have normal platelet count in NAIT; NAIT can occur in first pregnancy.	Hematology and blood bank; cranial ultrasound if <50 or suspected NAIT; maternal/infant/father platelet antigen and antibody testing.
Sick baby, early onset	Sepsis, perinatal asphyxia/HIE, DIC, severe respiratory disease, congenital infection, thrombosis, metabolic disease.	Acidosis, shock, coagulopathy, abnormal liver tests, bleeding/oozing, organ dysfunction.	CBC trend, PT/INR/aPTT, fibrinogen, D-dimer if DIC, cultures, CMV testing, imaging, and cause-directed therapy.
Late onset (>72 h)	Late-onset sepsis, NEC, central-line thrombosis, fungal infection, DIC, medication effect, bone-marrow suppression.	Worsening after initial stability; abdominal signs, temperature instability, rising CRP, line-related concerns.	Presume sepsis/NEC until proven otherwise; cultures, abdominal imaging if indicated, evaluate thrombosis and infection.
Persistent or syndromic	Congenital marrow failure, TAR, CAMT, Wiskott-Aldrich, trisomy, congenital leukemia/neuroblastoma.	Dysmorphism, skeletal anomalies, absent radii, hepatosplenomegaly, abnormal WBC, very small/large platelets.	Hematology/genetics; smear, marrow/genetic testing if indicated.

4. Evaluation Checklist

Domain	What to Check	Why It Matters
History	Maternal platelet count, ITP/SLE, splenectomy, thrombocytopenia during pregnancy, preeclampsia, HELLP, drugs, diabetes, consanguinity, prior miscarriages, prior sibling with thrombocytopenia or intracranial hemorrhage.	Separates NAUMT, NAIT, placental insufficiency, congenital/inherited causes, and recurrent-pregnancy risk.
Baby exam	Bleeding sites, petechiae/purpura, hepatosplenomegaly, dysmorphism, limb abnormalities, cataracts/rash, signs of infection, perfusion, and neurologic status.	Exam defines urgency, bleeding risk, and differential diagnosis.
Core labs	CBC with differential and smear; repeat platelet count if artifact suspected; PT/INR/aPTT; fibrinogen; D-dimer if DIC; blood gas/lactate; cultures if ill.	Confirms severity, detects DIC/sepsis, and identifies other cytopenias.
Infection tests	Blood culture as indicated; urine/saliva CMV PCR when persistent or unexplained; syphilis, rubella, toxoplasmosis, HIV, HSV/enterovirus guided by features and maternal status.	Congenital and acquired infections are important treatable causes.
Imaging	Cranial ultrasound for suspected NAIT, platelet count <50 × 10⁹/L, neurologic signs, significant bleeding, or severe unexplained thrombocytopenia.	NAIT has high intracranial hemorrhage risk and imaging changes transfusion targets.
NAIT testing	Send maternal, paternal, and infant samples for platelet antigen typing and maternal antiplatelet antibody testing; coordinate specimen tubes with hematology/blood bank.	Diagnosis guides HPA-compatible platelets and future pregnancy counseling.

5. General Management Principles

Treat the cause. Correct sepsis, NEC, DIC, hypoxia, acidosis, thrombosis, congenital infection, or medication exposure rather than repeatedly transfusing without a diagnosis.
Minimize iatrogenic bleeding. Use venipuncture rather than heel sticks when feasible; avoid IM injections, circumcision, and review invasive procedures with senior clinicians.
Use restrictive prophylactic transfusion in stable preterm infants. PlaNeT-2/MATISSE trial and follow-up support avoiding high prophylactic platelet thresholds in stable non-bleeding preterm infants.
Separate NAIT from ordinary thrombocytopenia. Suspected NAIT requires different thresholds, special platelet products when available, cranial ultrasound, and parental testing.
Document clearly. Record platelet count, trend, bleeding status, transfusion indication, product type, dose, response, and family discussion.

6. Platelet Transfusion Thresholds

How to use this table

These thresholds are bedside guardrails, not a substitute for hematology advice. Use lower thresholds for stable non-bleeding infants and higher thresholds for major bleeding, major surgery, or NAIT with intracranial hemorrhage risk.

The numbers behind the two immune thrombocytopenias (Baylor Ed. 33)

How common: thrombocytopenia affects 1–5% of all newborns, severe thrombocytopenia 0.1–0.5% — but 22–35% of NICU admissions and up to 50% of those needing intensive care.
NAIT: the HPA-1 antigen causes 75–90% of cases in Caucasian populations; HPA-4 is the commonest cause in Asian populations. Intracranial haemorrhage is reported in up to 20%, making NAIT the commonest cause of intracranial haemorrhage in term neonates. It can present in a first pregnancy. Suspect it in any infant under 7 days old with unexplained severe thrombocytopenia (usually <50 × 10⁹/L) who otherwise looks well.
NAIT transfusion thresholds differ from the general platelet guideline: <30 × 10⁹/L in an uncomplicated term infant, <50 × 10⁹/L in an uncomplicated preterm infant below 37 weeks, and <100 × 10⁹/L with major bleeding — intracranial, pulmonary, gastrointestinal or life-threatening. Check the count 20 minutes to 1 hour after transfusion, since the effect of random-donor platelets may be short-lived. IVIG 1 g/kg after the platelet transfusion may prolong their survival, though the evidence is limited. Glucocorticoids are not routinely indicated in NAIT.
NAUMT (maternal ITP or SLE): most infants are mildly affected and well, but 10–25% have severe thrombocytopenia. Intracranial haemorrhage is rare. Risk factors: maternal splenectomy, a maternal platelet count below 50,000/µL at any point in pregnancy, or a sibling with neonatal thrombocytopenia. Transfused platelets may work poorly because the maternal autoantibody attacks donor platelets too; IVIG 1 g/kg usually produces a rapid response, and glucocorticoids are reserved for IVIG-refractory cases.
Both conditions: check a platelet count after birth and at least daily until the nadir, which typically falls 2–5 days after birth. Arrange outpatient haematology follow-up for every infant with NAIT regardless of severity — parental testing guides future pregnancies.
Timing is a clue: thrombocytopenia that develops or worsens significantly after 72 hours is usually late-onset sepsis or NEC, not an immune cause.

Clinical Situation	Suggested Action	Important Notes
Platelets ≥50 × 10⁹/L and clinically stable with no bleeding	Usually do not transfuse; monitor trend and cause.	Avoid prophylactic transfusion solely because the count is below the adult normal range.
Platelets 25–49 × 10⁹/L, stable, no bleeding	Often observe with close monitoring; transfuse if additional risk factors present.	Risk factors: ELBW in first week, rapidly falling platelets, coagulopathy, current minor bleeding, prior major bleeding, planned procedure, indomethacin/ibuprofen exposure, or suspected NAIT with affected sibling.
Platelets <20–25 × 10⁹/L, stable infant	Transfuse after senior review.	Baylor uses <20 × 10⁹/L in some immune contexts; West Midlands uses <25 × 10⁹/L for otherwise well infants, including NAIT. Local policy may choose either boundary.
Platelets <50 × 10⁹/L with instability or risk factors	Transfuse.	Includes clinical instability, coagulopathy, BW <1000 g age <1 week, previous IVH/major bleeding, current minor bleeding, planned LP/central line/chest drain/surgery/exchange transfusion/ECMO, or falling count likely to cross 30.
Platelets <80–100 × 10⁹/L with active significant bleeding	Transfuse and treat underlying cause.	Belize recommends higher thresholds for active bleeding; Baylor/West Midlands use high targets for major bleeding/major surgery.
Major bleeding, intracranial hemorrhage, pulmonary hemorrhage, GI bleeding, or major surgery/neurosurgery	Aim for ≥100 × 10⁹/L until bleeding controlled or per hematology.	Also correct coagulopathy, fibrinogen, shock, acidosis, hypocalcemia, and hypothermia.
Suspected or confirmed NAIT without bleeding	Transfuse if <25–30 × 10⁹/L in term infants; consider <50 × 10⁹/L in preterm or high-risk scenarios.	Perform cranial ultrasound and use HPA-compatible platelets when available; do not delay random platelets in urgent cases.
NAIT with intracranial / major bleeding	Transfuse promptly; target ≥100 × 10⁹/L initially.	Consult hematology, transfusion medicine, and neurology/neurosurgery as indicated.

7. Product Selection and Administration

Situation	Preferred Product	Dose / Rate / Monitoring
Routine neonatal platelet transfusion	ABO/Rh-compatible if possible; CMV-negative or CMV-safe/leukoreduced platelets per local policy.	10–15 mL/kg over 30–60 min. Check post-transfusion platelet count per local policy, often within 12 hours.
Suspected / confirmed NAIT	HPA-compatible platelets when available; if unavailable, give random donor platelets immediately while compatible product is arranged.	Often 10–20 mL/kg; suspected NAIT may require 20 mL/kg. Check count 20–60 min after transfusion — response may be short-lived with incompatible platelets.
Refractory NAIT	HPA-negative platelets or washed/irradiated maternal platelets arranged by blood bank and hematology.	Remove incompatible plasma if maternal platelets are used; hematology and transfusion medicine must lead this process.
Immunodeficiency or prior intrauterine transfusion	Irradiated cellular blood components.	Irradiation is not routine for every platelet transfusion but is important in selected immune-risk situations; discuss with blood bank.
Administration safety	Do not administer platelets through an arterial line or UAC.	Use appropriate platelet/fresh-blood filter tubing; keep platelets at room temperature; infuse promptly; do not use routine diuretics after platelet transfusion.

8. Neonatal Autoimmune-Mediated Thrombocytopenia (NAUMT)

Item	Guideline Approach
Mechanism	Maternal autoantibodies from ITP, SLE, or similar autoimmune disorders cross the placenta and affect both maternal and fetal platelets.
Typical severity	Most neonates have mild thrombocytopenia; severe thrombocytopenia occurs in a minority and intracranial hemorrhage is uncommon.
Who needs monitoring?	Infants of mothers with ITP/SLE, maternal splenectomy, maternal platelet count <50 × 10⁹/L at any time, or sibling history of neonatal thrombocytopenia.
Monitoring	Obtain platelet count after birth or from cord sample; repeat at 24 hours and then daily until nadir is passed (usually days 2–5) if abnormal or high-risk.
Treatment	No treatment required for mild cases without bleeding. Consider platelet transfusion and IVIG 1 g/kg for clinically significant bleeding or very severe thrombocytopenia (<20–25 × 10⁹/L) with hematology input. Steroids reserved for rare refractory cases.
Discharge	Ensure platelet recovery or safe outpatient plan. West Midlands suggests discharge when platelet count is >100 × 10⁹/L, with a repeat count at approximately 2 weeks if IVIG was required.

9. Neonatal Alloimmune Thrombocytopenia (NAIT / FNAIT)

NAIT emergency rule

If suspected NAIT meets transfusion criteria, transfuse first and confirm later. Compatible platelets are best, but random donor platelets should not be withheld while waiting for HPA-matched product in a bleeding or very-low-count infant.

Step	Action
Recognize	Severe thrombocytopenia (<50 × 10⁹/L), petechiae/purpura, bleeding, or intracranial hemorrhage in an otherwise well term or preterm infant younger than 7 days. Maternal platelet count is usually normal.
Protect the brain	Obtain cranial ultrasound when platelet count is <50 × 10⁹/L or NAIT is suspected; repeat imaging if neurologic signs, bleeding, or persistently severe thrombocytopenia.
Call immediately	Notify neonatologist, hematology, and blood bank/transfusion medicine. Arrange transfer if special blood products or imaging support are unavailable.
Test correctly	Send maternal, paternal, and infant platelet antigen typing and maternal antiplatelet antibody testing. Do not delay treatment waiting for these results.
Transfuse	Use HPA-compatible platelets when available; if not, give random donor platelets urgently and arrange compatible product. Check response within 20–60 minutes.
Add IVIG if needed	Give IVIG 1 g/kg after platelet transfusion, or 1 g/kg/day for 1–3 days if severe thrombocytopenia, ongoing bleeding, or poor platelet survival.
Targets	Maintain platelets above 25–30 × 10⁹/L in uncomplicated term infants; above 50 × 10⁹/L in preterm/high-risk infants; near/above 100 × 10⁹/L with major bleeding or intracranial hemorrhage, using hematology guidance.
Counsel	Arrange outpatient hematology follow-up for all NAIT cases. Parental testing and fetal-medicine counseling are essential; recurrence risk and fetal bleeding risk in future pregnancies can be high.

10. Bedside Algorithm

Platelet count <150 × 10⁹/L → verify sample and classify as mild, moderate, severe, or very severe.
Assess bleeding and stability → if major bleeding or major surgery, transfuse and target high platelet count with hematology/transfusion support.
If well term/preterm infant <7 days with platelet count <50 × 10⁹/L → treat as suspected NAIT: hematology + blood bank + cranial ultrasound + platelet antigen/antibody testing + transfuse if threshold met.
If early mild–moderate thrombocytopenia with placental insufficiency/IUGR/preeclampsia and improving count → monitor trend; avoid unnecessary workup.
If late onset or sick infant → evaluate sepsis, NEC, DIC, thrombosis, congenital infection, and liver/metabolic disease; treat underlying cause.
Before invasive procedures, review platelet count, bleeding risk, coagulation profile, and urgency; transfuse if platelet count is below the procedure-specific threshold or bleeding risk is high.
After transfusion, document product, dose, indication, reaction surveillance, platelet response, and next count plan.

11. Source-Difference Notes and Practical Reconciliation

Topic	Source Variation	Practical Neonatology Academy Approach
Stable non-bleeding preterm infant	Older guidance often used 50 × 10⁹/L; PlaNeT-2/MATISSE showed harm with a 50 threshold compared with 25 in preterm infants.	Use restrictive prophylactic transfusion; do not transfuse stable non-bleeding infants solely for 25–49 × 10⁹/L unless additional risk factors exist.
NAUMT threshold	Baylor uses <20 × 10⁹/L for clinically significant bleeding or very low count; West Midlands uses <25 × 10⁹/L.	Use local policy; treat <20–25 × 10⁹/L or any clinically important bleeding with hematology input.
NAIT thresholds	Baylor differentiates term (<30), preterm (<50), and major bleeding (<100); West Midlands uses <25 for otherwise well or bleeding, and IVIG for <50 or persistent hemorrhage.	Use NAIT-specific thresholds with early hematology/blood bank involvement; do not use routine stable-preterm thresholds for suspected NAIT with high ICH risk.
HIE / therapeutic hypothermia	Belize suggests platelet transfusion at <100 × 10⁹/L in HIE receiving therapeutic hypothermia; many modern pathways individualize.	Consult hematology/transfusion service; consider bleeding, coagulopathy, procedure need, and center-specific hypothermia protocol.
Platelet product availability	HPA-compatible platelets may not be immediately available.	Do not delay urgent transfusion; give random donor platelets while compatible platelets are being arranged.

12. Monitoring, Documentation, and Quality Metrics

Area	Required Documentation / Metric
Before transfusion	Platelet count, sample type, bleeding status, stability, diagnosis suspected, procedure need, threshold used, family discussion when feasible.
Product safety	Product type, compatibility, CMV/leukoreduction/irradiation status if relevant, HPA compatibility if NAIT, dose in mL/kg, infusion duration.
After transfusion	Vital signs/reaction monitoring, post-count timing, platelet increment, next planned count, cause-directed treatment plan.
NAIT pathway metric	Time from severe platelet result to hematology/blood bank notification; time to cranial ultrasound; time to first platelet transfusion when indicated; follow-up arranged at discharge.
Stewardship metric	Percentage of stable non-bleeding preterm infants transfused at counts >25 × 10⁹/L without documented risk factor; aim to reduce unnecessary prophylactic exposure.

13. Parent Communication Script

Suggested language

"Your baby has a low platelet count. Platelets help stop bleeding. Some low counts improve by themselves, especially in premature or stressed babies, but very low counts can increase bleeding risk. We are checking the cause, watching for bleeding, and will give platelets only when the benefit is greater than the risk. If we suspect an immune cause called NAIT, we act quickly because it can affect the brain and can matter for future pregnancies."

Key Takeaways — Chapter 10.4

Classify thrombocytopenia by severity, timing (early vs. late), and whether the baby is well or sick — the differential and management diverge completely by this framework.
Well term infant <7 days with platelet count <50 × 10⁹/L = NAIT until proven otherwise; do not wait for serology to transfuse when thresholds are met.
Restrictive strategy in stable non-bleeding preterm infants: do not transfuse solely for 25–49 × 10⁹/L without additional risk factors (PlaNeT-2 evidence).
Use HPA-compatible platelets for NAIT when available; give random donor platelets immediately while compatible product is arranged — never delay for serology alone.
Cranial ultrasound is mandatory when platelet count is <50 × 10⁹/L in a well infant or suspected NAIT; intracranial hemorrhage risk is high and changes transfusion targets.
NAUMT is usually milder than NAIT; the platelet nadir is typically days 2–5 and spontaneous recovery is common, but monitoring is required.
For DIC, sepsis, or NEC: treat the underlying cause — product support is supportive, not curative, and should be reserved for bleeding, very low counts, or procedures.
Always document: indication, threshold used, product details, post-transfusion count, reaction surveillance, and family communication.

Selected References and Evidence Base

Baylor College of Medicine. Guidelines for Acute Care of the Neonate, Edition 33, 2025–2026. Section 8.2: Platelet Disorders.
West Midlands Neonatal Operational Delivery Network. Neonatal Guidelines 2025–2028. Thrombocytopenia; Coagulopathy; Vitamin K.
Belize Ministry of Health. Neonatal Clinical Practice Guidelines 2018–2021. Blood Components Transfusion and Platelet Transfusion sections.
Curley A, Stanworth SJ, Willoughby K, et al. Randomized Trial of Platelet-Transfusion Thresholds in Neonates (PlaNeT-2). N Engl J Med. 2019;380:242–251. DOI: 10.1056/NEJMoa1807320.
Fustolo-Gunnink SF, et al. Two-year outcomes following a randomised platelet transfusion trial in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2023;108:452–457.
Winkelhorst D, Oepkes D, Lopriore E. Fetal and neonatal alloimmune thrombocytopenia: evidence-based antenatal and postnatal management strategies. Expert Rev Hematol. 2017;10:729–737.

Clinical governance note

This is an educational guideline synthesis. For patient care, use local transfusion-service policies, blood product availability, neonatal hematology consultation, and institutional neonatal thresholds.